QP-Brain®
Quibim S.L. • Radiology • 12/13/2023
Device Purpose
QP-Brain® is a software application that utilizes automated image processing techniques, including artificial intelligence, to analyze brain MRI scans for quantitative volumetric measurements of brain structures and white matter hyperintensities. The system aims to provide clinicians with objective data from 3D T1-weighted and T2 FLAIR MR images to support the assessment of structural brain changes in adult and adolescent patients, with outputs comparable to normative data and suitable for longitudinal tracking.
Summary
QP-Brain® is a medical image processing software designed to assist clinicians in assessing structural MRIs for adults and adolescents aged 18 and older. It automates the labeling and volumetric quantification of segmentable brain structures using 3D T1-weighted MRI scans, and identifies white matter hyperintensities (WMH) from T2 FLAIR images, employing artificial intelligence for WMH detection. The system's workflow involves checking MR image compatibility, then an automated pipeline performs artifact correction, segmentation, atlas-based parcellation, volume calculation, and generates reports. The outputs, including segmented images and quantitative data, are compatible with DICOM workstations and PACS and can be compared against normative data if patient age and gender are provided, and it allows for longitudinal information reporting. The performance of QP-Brain® was assessed by comparing its automated segmentations to manual expert segmentations as a reference standard. For volumetric analysis of brain structures such as Gray Matter, White Matter, Cerebrospinal Fluid, and Intracranial Volume from T1 MRIs, the software showed high agreement, with DICE scores generally above 0.95 (e.g., GM 0.983, WM 0.990) and relatively small volume differences. In the quantification of White Matter Hyperintensities from T2 FLAIR images, performance, measured by DICE scores and absolute volume error, varied depending on the WMH load, with DICE scores ranging from approximately 0.4-0.5 for low WMH to over 0.8 for very high WMH. The software also demonstrated a Pearson’s correlation coefficient of 0.88 for WMH count.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of QP-Brain® in quantifying white matter hyperintensities (WMH) vary across different MRI scanner manufacturers, field strengths, and acquisition protocols?; What specific artificial intelligence algorithms are employed for WMH segmentation, how were they trained and validated, and what is their robustness to atypical WMH presentations or image artifacts?; Could you elaborate on the demographic characteristics, size, and source of the normative database used for percentile comparisons, and how it accounts for variables like ethnicity or education level?; For longitudinal analysis, what are the specific image registration and processing techniques used to ensure accurate and reliable quantification of changes over time, especially with varying scan intervals or slight protocol differences?; Beyond volumetric data, does QP-Brain® offer any information on the spatial distribution or morphological characteristics of segmented brain structures or WMH, which could be clinically relevant?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Post-§524B but no clear network capability detected
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.
• Cybersecurity risk assessment not referenced in AI-generated device summary. FDA cybersecurity guidance (2023) expects this for cyber devices.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly